KCNQ2 and Tinnitus: Pharmacological activation of KCNQ channels by retigabine, an FDA approved anti-epileptic drug that activates KCNQ2-5, or by SF0034, a potent KCNQ2/3 activator, prevent seizures, neuropathic pain and the development of tinnitus (Gunthorpe et al., 2012; Li et al., 2013; Kalappa et al., 2015).